CLAIMS
1. A freeze dried pharmaceutical FVIII formulation, wherein said formulation comprises a FVIII molecule having an increased in vivo circulatory half-life compared to wt FVIII, wherein said formulation, following reconstitution, is an aqueous isotonic formulation comprising 250-10.OOOIU/mL of said FVIII molecule, 2-7 mg NaCI/mL, 0.5-5.0 mg CaCI2, 2H20/ml_, and 50-110 mg sucrose/mL
2. A pharmaceutical formulation according to claim 1, wherein said formulation does not contain any preservatives.
3. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation further comprises 0.5-5 mg histidine/mL, 0.5-15 mg methionine/mL, and 0.05-0.4 mg surfactant/mL, and wherein the volume of said reconstituted formulation is 0.3-1.2 ml_, and the osmolality is 350- 500 mOsm/kg.
4. A pharmaceutical formulation according to any one of the preceding claims, wherein said FVIII molecule is a B domain truncated molecule having a B domain linker of 15-25 amino acids, wherein said FVIII molecule is conjugated with a half-life extending moiety via an O-glycan linked to the Ser750 amino acid residue according to SEQ ID NO 1, and wherein said FVIII molecule is conjugated with a water soluble polymer selected from PEG and heparosan.
5. A pharmaceutical formulation according to any one of the preceding claims, wherein said FVIII molecule is a fusion molecule, and wherein the fusion partner of said fusion molecule is selected from the list consisting of: albumin, an Fc domain, and an Fc receptor.
6. pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 lll/mL, 3.1 mg histidine/mL, 2.5 mg methionine/mL, 3.0 mg NaCI /mL, 80 mg sucrose/mL, 0.4 mg non-ionic surfactant/mL, and 3 mg CaCI2, 2H20/mL
7. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 3.1 mg histidine/mL, 2.5 mg

methionine/mL, 3.5 mg NaCI /ml_, 70 mg sucrose/mL, 0.4 mg non-ionic surfactant/mL, and 0.5-2 mg CaCI2, 2H20/mL.
8. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL of said FVIII molecule, 3.1 mg histidine/mL, 2.5 mg methionine/mL, 3.5 mg NaCI /ml_, 90 mg sucrose/mL, 0.4 mg non-ionic surfactant/mL, and 2 mg CaCI2, 2H2C7mL.
9. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 3.1 mg histidine/mL, 2.5 mg methionine/mL, 4 mg NaCI /mL, 80-100 mg sucrose/mL, 0.1-0.4 mg non-ionic surfactant/mL, and 2 mg CaCI2, 2H20/mL.

10. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 3.1 mg histidine/mL, 2.5 mg methionine/mL, 4-6 mg NaCI /mL, 100 mg sucrose/mL, 0.1-0.4 mg non-ionic surfactant/mL, and 2 mg CaCI2, 2H20/mL.
11. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 3.1 mg histidine/mL, 2.5 mg methionine/mL, 4 mg NaCI /mL, 70-90 mg sucrose/mL, 0.1-0.4 mg non-ionic surfactant/mL, and 1-5 mg CaCI2, 2H20/mL.
12. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 1-4 mg histidine/mL, 2.5 mg methionine/mL, 7 mg NaCI /mL, 100 mg sucrose/mL, 0.4 mg non-ionic surfactant/mL, and 2 mg CaCI2, 2H20/mL.
13. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation comprises 250-10,000 IU FVIII/mL, 1.5 mg/ml histidine, 2.5 mg methionine/mL, 3.5 mg NaCI /mL, 70 mg sucrose/mL, 0.4 mg non-ionic surfactant/mL, and 0.5-1 mg CaCI2, 2H20/mL.

14. A pharmaceutical formulation according to any one of the preceding claims, wherein the amount of oxidized FVIII light chain molecules is below 5% of the total amount of FVIII following storage of the formulation at 30°C for three months.
15. A pharmaceutical formulation according to any one of the preceding claims, wherein the formulation is reconstituted in 10 mM histidine solution, and wherein the volume of the reconstituted formulation is up to1 ml_.
16. A pharmaceutical formulation according to any one of the preceding claims, wherein the freeze dried formulation, prior to reconstitution, is a pharmaceutically elegant freeze dried cake with a volume that essentially corresponds to the fill volume before freeze drying.
17. A freeze dried pharmaceutical FVIII formulation according to any one of the preceding claims, wherein the amount of oxidized FVIII light chain molecules is below 5% of the total amount of FVIII, following storage at 30°C for 3 months.
18. A process for making a freeze dried pharmaceutical formulation according to any one of the preceding claims, wherein said process comprises the steps of (i) degassing the liquid formulation under low pressure, (ii) pressure equilibrating the degassed formulation with an inert gas, and (iii) freeze drying the degassed formulation.
19. A pharmaceutical formulation obtained by the method according to claim 18.
20. A pharmaceutical formulation according to any one of the preceding claims, wherein said formulation is for subcutaneous administration.
21. A pharmaceutical formulation according to any one of claims 1-18, wherein said formulation is for intravenous administration.
22. A pharmaceutical formulation according to any of claims 1-18 for use in treatment of haemophilia A.